Urinary Tract Infection (UTI) Treatment Market By Drug Type (Penicillin, Quinolones, Cephalosporin, Sulphonamides, Tetracycline, Other) - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025

Urinary tract infection (UTI) is the most common type of infection; it involves infection of the kidneys, ureters, bladder, or urethra. The UTI treatment market is rapidly growing due to factors such as the growing prevalence of UTI, significant unmet needs, and the rising number of drug-resistant bacteria due to excessive use of antibiotics.

The report titled "Urinary Tract Infection (UTI) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall UTI treatment market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class (penicillin, quinolones, cephalosporins, sulphonamides, tetracyclines, and others) and different geographical regions.

Geographically, the global UTI treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global UTI treatment market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global UTI treatment market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global UTI treatment market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global UTI treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global urinary tract infection (UTI) treatment market is segmented as follows:

  • Penicillin
  • Quinolones
  • Cephalosporin
  • Sulphonamides
  • Tetracycline
  • Other

Urinary tract infection (UTI) is the most common type of infection; it involves infection of the kidneys, ureters, bladder, or urethra. Some factors, such as the growing prevalence of UTI, the rising incidence of risk factors such as diabetes and kidney stones, early diagnosis of UTI, and changing lifestyle patterns, are prime factors that are driving the growth of the UTI treatment market globally. Drug resistance due to the excessive use of antibiotics and the increasing number of drug-resistant bacteria are other factors that would assist market growth during the forecast period. For the purpose of the study, the UTI treatment market is segmented on the basis of drug classes, such as penicillin, quinolones, cephalosporins, sulphonamides, tetracyclines, and others. It is observed that, in the base year 2016, demand for quinolones was highest on the market, as these are preferred as first-line treatment options due to their higher bioavailability and fewer side effects. Physicians generally prescribe a quinolone medicine if there are no other existing treatment options remaining for the treatment of a complicated UTI or kidney infection.

For the purpose of this study, the global urinary tract infection (UTI) treatment market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Urinary tract infection (UTI) is one of the most common types of infections occurring in any part of the urinary tract, such as the ureters, kidneys, urethra, or bladder. According to the World Health Organization (WHO), approximately 50% of women report having a UTI at some point in their lives. Among the considered geographical segments, North America was a major revenue contributor in 2016. Early diagnosis, higher treatment awareness, swift adoption of novel medications, and better reimbursement policies in healthcare systems are the prime contributors to North America's dominance. Higher expenditure on healthcare in the United States as compared to other nations is another factor contributing to market growth in North America. According to the Urology Foundation of America, 1 in 5 women will develop UTIs in their lifetime in America. However, due to rising healthcare awareness among the general patient population, a growing number of investments and partnerships between key players and local manufacturers are expected to assist the UTI treatment market's growth in Asia-Pacific.

Frequently Asked Questions:

The market for Urinary Tract Infection (UTI) Treatment is expected to reach US$ xx Bn in 2025.

The Urinary Tract Infection (UTI) Treatment market is expected to see significant CAGR growth over the coming years,at 3.2%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

AstraZeneca plc.,Bayer AG,Cubist Pharmaceuticals,F. Hoffmann–La Roche Ltd.,GlaxoSmithKline Pharmaceuticals Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Oct 2017
Category:  Pharmaceuticals
Report ID:   58749
Report Format:   PDF
Pages:   120
Rating:    4.8 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support